Welcome to our dedicated page for ICON news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON stock.
ICON plc reports developments for a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology companies. Its news commonly covers operating and financial results, clinical trial management activity, net business wins, revenue guidance, and service areas such as patient recruitment, data analytics, laboratory services and regulatory consulting.
Company updates also address partnerships that connect clinical trial technology with research-site systems, expansion of the Accellacare Site Network in therapeutic areas including oncology, and governance or accounting-control matters tied to revenue recognition and financial reporting.
ICON (NASDAQ: ICLR) announced that its wholly owned subsidiary, ICON Investments Six Designated Activity Company, intends to privately offer one or more series of senior notes with registration rights, subject to market and other conditions. The notes will be guaranteed on a senior unsecured basis by ICON.
According to ICON, net proceeds are intended to repay all outstanding borrowings under its bridge facility credit agreement, repay all outstanding term loans under its senior secured term loan facility, and redeem in full the Issuer’s outstanding 5.809% Senior Secured Notes due 2027. Upon repayment of the bridge facility and term loans, collateral securing ICON’s revolving credit facility and existing notes, and related subsidiary guarantees, would be automatically released. The notes are being offered to qualified institutional buyers under Rule 144A and to certain investors outside the United States under Regulation S, and are not registered under the Securities Act. ICON cautions there is no assurance the offering, related repayments or collateral releases will be completed.
ICON (NASDAQ: ICLR) reported that all resolutions at its Annual General Meeting held on 31 July 2026 were duly passed by shareholders, based on 68,388,626 total votes cast on each item.
Shareholders re-elected or elected ten directors, including Ciaran Murray, Barry Balfe, Rónán Murphy, John Climax, Julie O’Neill, Eugene McCague, Linda Grais, Anne Whitaker, Kevin Egan and Jeff Elliott, with more votes for than against in every case.
Investors also approved reviewing the company’s affairs and accounts, authorising the fixing of the auditors’ remuneration, granting authority to allot shares, and enabling overseas market purchases of shares. Special resolutions disapplying statutory pre-emption rights, including for funding capital investment or acquisitions, and setting the price range for reissuing treasury shares, were likewise approved.
ICON (NASDAQ: ICLR) reported second quarter 2026 revenue of $2,063.5 million, up 1.2% year over year and 1.4% versus Q1 2026. Gross bookings were $3,681 million, up 24.1% year over year, yielding net business wins of $3,120 million and a book‑to‑bill of 1.51. Backlog at June 30, 2026 reached $23.4 billion, up 3.0% sequentially.
GAAP net income was $72.6 million (diluted EPS $0.94) versus $2.56 a year earlier. Adjusted net income was $198.4 million with adjusted diluted EPS of $2.56, down from $3.52. Adjusted EBITDA declined 21.7% year over year to $327.2 million, or 15.9% of revenue. Free cash flow was $238.9 million, and net debt was $2.5 billion (1.8x adjusted EBITDA). ICON reaffirmed 2026 guidance, targeting revenue of $7,850–$8,150 million and adjusted diluted EPS of $10.00–$11.00.
ICON (NASDAQ: ICLR) announced a multi-year collaboration with Anthropic to embed Claude’s frontier AI across the clinical trial lifecycle via ICON’s secure, governed Orbis platform. ICON and Anthropic’s Life Sciences research team will co-develop AI-driven capabilities spanning site intelligence, predictive operations, protocol optimisation and ecosystem integration.
According to ICON, Orbis will gain four production capabilities: enhanced site selection and study planning within OneSearch and OnePlan, real-time enrolment and operational risk detection, AI-assisted protocol design and scenario modelling, and secure integration of ICON’s clinical expertise into client systems via Claude. ICON plans a role-based rollout of Claude Code for developers, Claude for knowledge teams and Claude Science for scientific and clinical teams, aiming to automate high-volume work and embed domain-specific AI agents directly into clinical development workflows.
ICON (NASDAQ: ICLR) will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. A conference call and webcast to discuss performance will follow on Thursday, July 30, 2026 at 8:00am ET, with access details and any updates posted in the Investor “Events” section of its website.
A webcast replay will be available about one hour after the call. ICON, headquartered in Dublin, employs approximately 40,350 people across 97 locations in 55 countries as of March 31, 2026, providing global clinical research and commercialization services.
ICON (NASDAQ: ICLR) reported first quarter 2026 revenue of $2,034.0 million, up 0.9% year over year (down 1.9% in constant currency). GAAP net income was $104.8 million, or $1.36 diluted EPS. Adjusted diluted EPS was $2.50.
Adjusted EBITDA was $317.7 million (15.6% margin), down 20.2% versus Q1 2025. Net business wins reached $2,880 million, with a book-to-bill of 1.42 and backlog of $22.7 billion. ICON reaffirmed 2026 guidance for revenue of $7,850–$8,150 million and adjusted EPS of $10.00–$11.00.
ICON (NASDAQ: ICLR) selected Microsoft as a preferred technology partner to advance its three‑year digital innovation and AI plan. The collaboration includes enterprise‑wide deployment of Microsoft 365 Copilot and Azure‑based cloud, data and AI infrastructure to scale Orbis, ICON’s secure agentic AI platform.
The partnership targets four areas across the clinical trial lifecycle: AI‑enabled study design, operational execution, patient and site engagement, and real‑time decision‑making. It aligns with ICON’s AI strategy focus on a unified intelligence layer, company‑wide productivity gains, and domain‑specific agents embedded directly into clinical workflows.
ICON (NASDAQ: ICLR) will release its first quarter 2026 financial results after market close on Tuesday, June 23, 2026. Management will host a conference call and webcast to discuss results and performance on Wednesday, June 24, 2026 at 8:00am ET.
Event updates, webcast links, and a replay (available about one hour after the call) will be accessible in the Investor section of the company website under Events.
ICON (NASDAQ: ICLR) reported Q4 2025 revenue of $2,112.5M and full-year 2025 revenue of $8,251.3M, with adjusted EBITDA of $327.1M in Q4 and $1,530.7M for 2025.
The Audit Committee completed its investigation, leading to small revenue restatements for 2023–2024, identified material control weaknesses, updated backlog policies and issued 2026 guidance of $7,850–$8,150M revenue and $10.00–$11.00 adjusted EPS.
ICON (NASDAQ: ICLR) will release fourth quarter and full year 2025 results after market close on May 27, 2026, followed by a conference call on May 28, 2026 at 8:00 a.m. ET. ICON also received a Nasdaq Listing Rule 5250(c)(1) deficiency notice due to its pending 2025 Form 20-F filing.
The notice does not immediately affect listing or trading. ICON has 60 days to submit a compliance plan and expects to regain compliance by filing the Form 20-F before the earnings call.